Evaluation of a treatment planning system developed for clinical boron neutron capture therapy and validation against an independent Monte Carlo dose calculation system.


Journal

Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111

Informations de publication

Date de publication:
24 Dec 2021
Historique:
received: 06 08 2021
accepted: 15 12 2021
entrez: 25 12 2021
pubmed: 26 12 2021
medline: 20 1 2022
Statut: epublish

Résumé

Boron neutron capture therapy (BNCT) for the treatment of unresectable, locally advanced, and recurrent carcinoma of the head and neck cancer has been approved by the Japanese government for reimbursement under the national health insurance as of June 2020. A new treatment planning system for clinical BNCT has been developed by Sumitomo Heavy Industries, Ltd. (Sumitomo), NeuCure® Dose Engine

Identifiants

pubmed: 34952608
doi: 10.1186/s13014-021-01968-2
pii: 10.1186/s13014-021-01968-2
pmc: PMC8709965
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

243

Informations de copyright

© 2021. The Author(s).

Références

J Neurooncol. 1997 May;33(1-2):93-104
pubmed: 9151227
Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S37-42
pubmed: 19409799
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Jpn J Clin Oncol. 2007 May;37(5):376-81
pubmed: 17578894
Appl Radiat Isot. 2011 Dec;69(12):1642-5
pubmed: 21463945
Med Phys. 1998 May;25(5):656-61
pubmed: 9608475
Radiother Oncol. 2008 Aug;88(2):192-5
pubmed: 18653257
Med Phys. 2018 Apr;45(4):e53-e83
pubmed: 29443390
J Neurooncol. 2020 Aug;149(1):1-11
pubmed: 32676954
Australas Phys Eng Sci Med. 2003 Sep;26(3):97-103
pubmed: 14626847
Radiat Res. 1991 Apr;126(1):1-20
pubmed: 2020734
Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1121-9
pubmed: 8262837
J Neurooncol. 2003 Mar-Apr;62(1-2):75-86
pubmed: 12749704
J Neurooncol. 2009 Jan;91(2):199-206
pubmed: 18813875
Appl Radiat Isot. 2020 Dec;166:109222
pubmed: 32755755
Neurooncol Adv. 2021 May 20;3(1):vdab067
pubmed: 34151269
Med Phys. 2011 Jan;38(1):504-30
pubmed: 21361219
Med Phys. 2002 Feb;29(2):145-56
pubmed: 11865986
Med Phys. 2002 Aug;29(8):1710-5
pubmed: 12201417
Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):383-97
pubmed: 8635948
Radiat Res. 1998 Feb;149(2):163-70
pubmed: 9457896
Radiat Res. 1995 Dec;144(3):310-7
pubmed: 7494875
Rev Sci Instrum. 2017 Nov;88(11):113302
pubmed: 29195381

Auteurs

Naonori Hu (N)

Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan. naonori.ko@ompu.ac.jp.
Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kyoto, Japan. naonori.ko@ompu.ac.jp.

Hiroki Tanaka (H)

Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kyoto, Japan.

Ryo Kakino (R)

Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan.

Syuushi Yoshikawa (S)

Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan.

Mamoru Miyao (M)

Central Department of Radiology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan.

Kazuhiko Akita (K)

Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan.

Kayako Isohashi (K)

Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan.

Teruhito Aihara (T)

Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan.

Keiji Nihei (K)

Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan.
Department of Radiation Oncology, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan.

Koji Ono (K)

Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Osaka-fu Takatsuki-shi Daigakumachi 2-7, Takatsuki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH